[Federal Register Volume 69, Number 197 (Wednesday, October 13, 2004)]
[Notices]
[Page 60898]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 04-22935]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Application

    Pursuant to 21 CFR 1301.33(a), this is notice that on July 8, 2004, 
Chattem Chemicals, Inc., 3801 St. Elmo Avenue, Building 18, 
Chattanooga, Tennessee, made application by renewal to the Drug 
Enforcement Administration (DEA) for registration as a bulk 
manufacturer of the basic classes of controlled substances listed:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
N-Ethylamphetamine (1475)..................  I
4-Methoxyamphetamine (7411)................  I
2,5-Dimethoxyamphetamine (7396)............  I
Difenoxin (9168)...........................  I
Amphetamine (1100).........................  II
Methamphetamine (1105).....................  II
Methylphenidate (1724).....................  II
Pentobarbital (2270).......................  II
Secobarbital (2315)........................  II
Codeine (9050).............................  II
Oxycodone (9143)...........................  II
Diphenoxylate (9170).......................  II
Hydrocodone (9193).........................  II
Meperidine (9230)..........................  II
Dextropropoxyphene, bulk (9273)............  II
Morphine (9300)............................  II
Thebaine (9333)............................  II
Alfentanil (9737)..........................  II
Sufentanil (9740)..........................  II
Fentanyl (9801)............................  II
------------------------------------------------------------------------

    The company plans to manufacture the listed controlled substances 
in bulk for distribution to its customers.
    Any other such applicant and any person who is presently registered 
with DEA to manufacture such a substance may file comments or 
objections to the issuance of the proposed registration pursuant to 21 
CFR 1301.33(a).
    Any such comments or objections may be addressed, in quintuplicate, 
to the Deputy Assistant Administrator, Office of Diversion Control, 
Drug Enforcement Administration, United States Department of Justice, 
Washington, DC 20537, Attention: DEA Federal Register Representative 
(CCD) and must be filed no later than December 13, 2004.

    Dated: September 28, 2004.
William J. Walker,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 04-22935 Filed 10-12-04; 8:45 am]
BILLING CODE 4410-09-P